{"id":2892,"date":"2026-10-14T15:40:33","date_gmt":"2026-10-14T15:40:33","guid":{"rendered":"https:\/\/nietolawyers.com\/en\/?post_type=actualidad&#038;p=2892"},"modified":"2026-10-14T15:40:34","modified_gmt":"2026-10-14T15:40:34","slug":"clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros","status":"publish","type":"actualidad","link":"https:\/\/nietolawyers.com\/en\/actualidad\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\/","title":{"rendered":"Clinical Trials in Colombia: INVIMA Requirements for Foreign Sponsors &amp; CROs"},"content":{"rendered":"\n<style>\n.nnl-ct{--nc-navy:#0d2a45;--nc-navy2:#17426d;--nc-gold:#c9a46a;--nc-gold-dark:#a8823f;--nc-gold2:#dcc08f;--nc-cream:#f8f3ea;--nc-ink:#24303f;--nc-muted:#5d6878;--nc-line:#e4e7ec;--nc-bg:#f5f7fa;color:var(--nc-ink);font-size:17px;line-height:1.75;max-width:880px;margin:0 auto}\n.nnl-ct *,.nnl-ct *::before,.nnl-ct *::after{box-sizing:border-box}\n.nnl-ct p{margin:0 0 1.1em}\n.nnl-ct a{text-decoration:none}\n.nnl-ct h2{font-size:clamp(1.45rem,2.4vw,1.9rem);line-height:1.3;color:var(--nc-navy);font-weight:700;margin:2.8em 0 1em;padding:0;letter-spacing:-.01em}\n.nnl-ct h3{font-size:1.18rem;line-height:1.4;color:var(--nc-navy);font-weight:700;margin:1.8em 0 .7em}\n.nnl-ct .nc-eyebrow{margin:2.8em 0 .5em;font-size:.82em;font-weight:700;letter-spacing:.08em;text-transform:uppercase;color:var(--nc-gold-dark);line-height:1.5}\n.nnl-ct .nc-eyebrow + h2{margin-top:0}\n.nnl-ct .nc-figure{margin:0 0 1.8em;border-radius:16px;overflow:hidden;box-shadow:0 14px 34px rgba(13,42,69,.14);background:var(--nc-bg)}\n.nnl-ct .nc-figure img{display:block;width:100%;height:auto;aspect-ratio:16\/9;object-fit:cover;margin:0;border:0}\n.nnl-ct .nc-lead{font-size:1.22em;line-height:1.55;font-weight:700;color:var(--nc-navy);border-left:4px solid var(--nc-gold);padding:4px 0 4px 20px;margin:0 0 1.3em}\n.nnl-ct .nc-key{margin:1.6em 0;padding:26px 30px;border-radius:14px;background:linear-gradient(135deg,var(--nc-navy),var(--nc-navy2));color:#fff;font-size:1.05em;line-height:1.6;box-shadow:0 12px 28px rgba(13,42,69,.18)}\n.nnl-ct .nc-key p{margin:0;color:#fff}\n.nnl-ct .nc-key strong{color:var(--nc-gold2)}\n.nnl-ct .nc-note{margin:1.6em 0;padding:20px 24px;background:var(--nc-bg);border-left:4px solid var(--nc-gold);border-radius:0 12px 12px 0}\n.nnl-ct .nc-note p{margin:0}\n.nnl-ct .nc-note strong{color:var(--nc-navy)}\n.nnl-ct .nc-box{margin:1.6em 0;padding:26px 28px;border-radius:14px;background:#fff;border:1px solid var(--nc-line);border-top:4px solid var(--nc-gold);box-shadow:0 10px 26px rgba(13,42,69,.07)}\n.nnl-ct .nc-box h3{margin:0 0 .6em;display:flex;align-items:center;gap:12px}\n.nnl-ct .nc-box-icon{flex:0 0 38px;height:38px;border-radius:10px;background:var(--nc-cream);display:inline-flex;align-items:center;justify-content:center}\n.nnl-ct .nc-box p:last-child{margin:0}\n.nnl-ct .nc-box strong{color:var(--nc-navy)}\n.nnl-ct .nc-cta-top{margin:2em 0 1em;padding:30px 32px;border-radius:18px;background:linear-gradient(135deg,var(--nc-navy),var(--nc-navy2));color:#e9eef5;box-shadow:0 16px 36px rgba(13,42,69,.22);display:grid;grid-template-columns:1fr auto;gap:24px;align-items:center}\n.nnl-ct .nc-cta-top h3{color:#fff;margin:0 0 .4em;font-size:1.3rem}\n.nnl-ct .nc-cta-top p{margin:0;color:#e9eef5}\n.nnl-ct .nc-btn{display:inline-flex;align-items:center;justify-content:center;padding:15px 24px;border-radius:10px;background:var(--nc-gold);color:var(--nc-navy)!important;font-weight:800;font-size:.9em;letter-spacing:.04em;line-height:1.3;text-align:center;text-decoration:none!important;box-shadow:0 8px 20px rgba(201,164,106,.35);transition:transform .2s,background .2s,box-shadow .2s}\n.nnl-ct .nc-btn:hover{background:var(--nc-gold2);transform:translateY(-2px);box-shadow:0 12px 26px rgba(201,164,106,.45)}\n.nnl-ct .nc-btn.is-navy{background:var(--nc-navy);color:#fff!important;box-shadow:0 8px 20px rgba(13,42,69,.25)}\n.nnl-ct .nc-btn.is-navy:hover{background:var(--nc-navy2)}\n.nnl-ct .nc-pair{display:grid;grid-template-columns:1fr 1fr;gap:16px;margin:1.4em 0}\n.nnl-ct .nc-pair-card{padding:24px;border-radius:14px;border:1px solid var(--nc-line);background:#fff;position:relative}\n.nnl-ct .nc-pair-card.is-a{border-top:4px solid var(--nc-navy)}\n.nnl-ct .nc-pair-card.is-b{border-top:4px solid var(--nc-gold)}\n.nnl-ct .nc-pair-card p{margin:0}\n.nnl-ct .nc-checks{list-style:none!important;display:grid;grid-template-columns:repeat(2,minmax(0,1fr));gap:12px;margin:1em 0 1.6em!important;padding:0!important}\n.nnl-ct .nc-checks li{position:relative;margin:0!important;padding:14px 16px 14px 48px;background:#fff;border:1px solid var(--nc-line);border-radius:12px;line-height:1.5;font-size:.96em;transition:border-color .2s,box-shadow .2s}\n.nnl-ct .nc-checks li:hover{border-color:var(--nc-gold2);box-shadow:0 6px 18px rgba(13,42,69,.08)}\n.nnl-ct .nc-checks li::before{content:\"\";position:absolute;left:16px;top:16px;width:20px;height:20px;border-radius:50%;background:var(--nc-gold) url(\"data:image\/svg+xml,%3Csvg xmlns='http:\/\/www.w3.org\/2000\/svg' viewBox='0 0 24 24' fill='none' stroke='white' stroke-width='3.5' stroke-linecap='round' stroke-linejoin='round'%3E%3Cpolyline points='20 6 9 17 4 12'\/%3E%3C\/svg%3E\") center\/12px no-repeat}\n.nnl-ct .nc-streams-title{font-weight:700;color:var(--nc-navy);margin:1.6em 0 .8em}\n.nnl-ct .nc-streams{display:grid;grid-template-columns:1fr 1fr;gap:18px;margin:0 0 1.6em}\n.nnl-ct .nc-stream{border-radius:16px;overflow:hidden;border:1px solid var(--nc-line);background:#fff;box-shadow:0 10px 24px rgba(13,42,69,.07)}\n.nnl-ct .nc-stream h3{margin:0;padding:16px 22px;font-size:1.08rem;color:#fff;background:var(--nc-navy);display:flex;align-items:center;gap:10px}\n.nnl-ct .nc-stream.is-b h3{background:var(--nc-gold-dark)}\n.nnl-ct .nc-stream ul{list-style:none!important;margin:0!important;padding:18px 22px!important;display:flex;flex-wrap:wrap;gap:8px}\n.nnl-ct .nc-stream li{margin:0!important;padding:7px 14px;border-radius:999px;background:var(--nc-bg);border:1px solid var(--nc-line);font-size:.92em;font-weight:600;color:var(--nc-navy);line-height:1.3}\n.nnl-ct .nc-stream.is-b li{background:var(--nc-cream);border-color:#eadfcb}\n.nnl-ct .nc-ready{margin:3em 0;border-radius:20px;overflow:hidden;background:linear-gradient(160deg,var(--nc-navy) 0%,var(--nc-navy2) 100%);color:#e9eef5;box-shadow:0 20px 44px rgba(13,42,69,.25)}\n.nnl-ct .nc-ready-head{padding:34px 38px 26px}\n.nnl-ct .nc-ready h2{color:#fff;margin:0}\n.nnl-ct .nc-ready-img img{display:block;width:100%;height:auto;aspect-ratio:16\/8;object-fit:cover;margin:0;border:0}\n.nnl-ct .nc-ready-body{padding:30px 38px 36px}\n.nnl-ct .nc-ready-body p{color:#e9eef5}\n.nnl-ct .nc-ready .nc-checks li{background:rgba(255,255,255,.07);border-color:rgba(255,255,255,.15);color:#fff}\n.nnl-ct .nc-ready .nc-checks li:hover{border-color:var(--nc-gold2);box-shadow:none}\n.nnl-ct .nc-ready .nc-checks{margin-bottom:0!important}\n.nnl-ct .nc-timeline{list-style:none!important;display:grid;grid-template-columns:repeat(6,minmax(0,1fr));margin:2em 0!important;padding:30px 18px 26px!important;background:var(--nc-cream);border-radius:18px;border:1px solid #eadfcb}\n.nnl-ct .nc-timeline li{position:relative;margin:0!important;padding:46px 6px 0;text-align:center;font-weight:700;color:var(--nc-navy);font-size:.92em;line-height:1.35}\n.nnl-ct .nc-timeline li::before{content:\"\";position:absolute;top:0;left:50%;transform:translateX(-50%);width:26px;height:26px;border-radius:50%;background:#fff;border:5px solid var(--nc-gold);z-index:2}\n.nnl-ct .nc-timeline li::after{content:\"\";position:absolute;top:11px;left:50%;width:100%;height:4px;background:var(--nc-gold2);z-index:1}\n.nnl-ct .nc-timeline li:last-child::after{display:none}\n.nnl-ct .nc-timeline li:first-child::before,.nnl-ct .nc-timeline li:last-child::before{background:var(--nc-navy);border-color:var(--nc-navy)}\n.nnl-ct .nc-btn-wrap{margin:1.6em 0}\n.nnl-ct .nc-final{margin:3em 0 1em;padding:36px;border-radius:20px;background:#fff;border:1px solid var(--nc-line);box-shadow:0 16px 40px rgba(13,42,69,.08)}\n.nnl-ct .nc-final .nc-eyebrow{margin-top:0}\n.nnl-ct .nc-final .nc-note{margin-bottom:0}\n@media (max-width:768px){.nnl-ct{font-size:16px}.nnl-ct .nc-pair,.nnl-ct .nc-checks,.nnl-ct .nc-streams{grid-template-columns:1fr}.nnl-ct .nc-cta-top{grid-template-columns:1fr;padding:26px 22px}.nnl-ct .nc-btn{width:100%}.nnl-ct .nc-ready-head,.nnl-ct .nc-ready-body{padding:26px 22px}.nnl-ct .nc-final{padding:26px 20px}.nnl-ct .nc-box{padding:22px 20px}.nnl-ct .nc-timeline{grid-template-columns:1fr;padding:24px 20px!important}.nnl-ct .nc-timeline li{text-align:left;padding:2px 0 26px 44px}.nnl-ct .nc-timeline li:last-child{padding-bottom:0}.nnl-ct .nc-timeline li::before{left:0;transform:none}.nnl-ct .nc-timeline li::after{top:13px;left:11px;width:4px;height:100%}}\n@media (max-width:480px){.nnl-ct .nc-figure{border-radius:12px}}\n<\/style>\n\n<div class=\"nnl-ct\">\n\n<p class=\"nc-lead\">Conducting a clinical trial in Colombia involves more than obtaining INVIMA approval.<\/p>\n<p>Foreign pharmaceutical companies, biotech companies and CROs must coordinate regulatory approval, ethics review, site qualification, healthcare-service habilitation, investigational-product logistics, safety reporting, data protection and contractual allocation of responsibilities.<\/p>\n<p>A deficiency in any of these areas may affect submission, site activation or the ongoing operation of the study.<\/p>\n<p>This guide explains the principal Colombian regulatory issues foreign sponsors and CROs should evaluate before conducting a clinical trial in Colombia.<\/p>\n\n<div class=\"nc-cta-top\">\n<div>\n<h3>Planning a Clinical Trial in Colombia?<\/h3>\n<p>We can review your proposed Colombian structure before submission or site activation and identify regulatory, contractual and operational issues requiring local action.<\/p>\n<\/div>\n<a class=\"nc-btn\" href=\"https:\/\/wa.me\/573156695219?text=Hello%2C%20I%20read%20your%20article%20on%20clinical%20trials%20in%20Colombia%20and%20I%20would%20like%20to%20request%20a%20regulatory%20assessment.\" target=\"_blank\" rel=\"noopener\">REQUEST A REGULATORY ASSESSMENT \u2192<\/a>\n<\/div>\n\n<h2>When Does a Drug Clinical Trial in Colombia Require INVIMA Approval?<\/h2>\n<figure class=\"nc-figure\"><img data-src=\"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/2-1.jpg\" alt=\"When Does a Drug Clinical Trial in Colombia Require INVIMA Approval\" width=\"1376\" height=\"768\" decoding=\"async\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1376px; --smush-placeholder-aspect-ratio: 1376\/768;\"><\/figure>\n<p>In Colombia, the National Institute for Food and Drug Surveillance (INVIMA) is the competent health authority for the evaluation and authorization of clinical trials involving medicines in human subjects.<\/p>\n<p>Under the current Colombian framework, Phase I, Phase II, Phase III and interventional Phase IV drug studies intended to be conducted in Colombia must be submitted to INVIMA through the <em>Protocolos en L\u00ednea<\/em> platform.<\/p>\n<p>Before the regulatory submission is filed, the study must also have been reviewed by a Research Ethics Committee (Comit\u00e9 de \u00c9tica en Investigaci\u00f3n or CEI) associated with an institution certified in Good Clinical Practices.<\/p>\n<p>Foreign regulatory approval does not replace the Colombian process. Authorization by the FDA, EMA or another foreign regulator does not eliminate the need to comply with the Colombian regulatory pathway.<\/p>\n<p>Medical-device clinical investigations follow a different regulatory route and should therefore be assessed separately.<\/p>\n<div class=\"nc-key\"><p><strong>For foreign sponsors:<\/strong> The Colombian regulatory pathway should be confirmed before adapting the global dossier or committing to a local site-activation timeline.<\/p><\/div>\n\n<h2>Before Selecting a Colombian Research Site, What Should a Sponsor Verify?<\/h2>\n<figure class=\"nc-figure\"><img data-src=\"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/3-1.jpg\" alt=\"Before Selecting a Colombian Research Site, What Should a Sponsor Verify\" width=\"1376\" height=\"768\" decoding=\"async\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1376px; --smush-placeholder-aspect-ratio: 1376\/768;\"><\/figure>\n<p>Site qualification in Colombia requires more than confirming that the institution has experience conducting clinical research.<\/p>\n<p>A foreign sponsor should distinguish between at least two separate regulatory controls.<\/p>\n<div class=\"nc-pair\">\n<div class=\"nc-pair-card is-a\"><p>First, the research institution must comply with the Good Clinical Practice requirements applicable to clinical research with medicines and, where required, hold the corresponding certification issued by INVIMA.<\/p><\/div>\n<div class=\"nc-pair-card is-b\"><p>Second, if the institution acts as a healthcare provider, the sponsor should verify that the healthcare services actually required to perform the protocol are duly habilitated under the Colombian healthcare-provider framework.<\/p><\/div>\n<\/div>\n<p>These are separate regulatory analyses. A site may therefore require review both from the clinical-research perspective and from the healthcare-service habilitation perspective.<\/p>\n<div class=\"nc-note\"><p><strong>Why this matters:<\/strong> Discovering a site deficiency after the institution has already been selected, contracted or incorporated into the global study timeline may create avoidable delays and contractual issues.<\/p><\/div>\n\n<h2>How Should Sponsor and CRO Responsibilities Be Allocated in Colombia?<\/h2>\n<figure class=\"nc-figure\"><img data-src=\"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/4-1.jpg\" alt=\"How Should Sponsor and CRO Responsibilities Be Allocated in Colombia\" width=\"1376\" height=\"768\" decoding=\"async\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1376px; --smush-placeholder-aspect-ratio: 1376\/768;\"><\/figure>\n<p>Colombian regulation recognizes that a Contract Research Organization (CRO) may perform one or more functions related to the clinical trial on behalf of the sponsor.<\/p>\n<p>In practice, a CRO may participate in regulatory submissions, site coordination, monitoring, pharmacovigilance, document management and other operational activities.<\/p>\n<p>However, the delegation of functions should be clearly documented. The sponsor\u2013CRO agreement should specify which party is responsible for each regulatory and operational obligation arising in Colombia.<\/p>\n<p>Particular attention should be given to responsibilities involving INVIMA submissions, Ethics Committee communications, amendments, informed-consent updates, safety reporting, investigational-product imports, biological-sample exports, monitoring, annual reporting and study closure.<\/p>\n<div class=\"nc-box\">\n<h3><span class=\"nc-box-icon\" aria-hidden=\"true\"><svg width=\"20\" height=\"20\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"#a8823f\" stroke-width=\"2.2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><rect x=\"3\" y=\"3\" width=\"18\" height=\"18\" rx=\"2\"\/><path d=\"M3 9h18\"\/><path d=\"M3 15h18\"\/><path d=\"M9 3v18\"\/><\/svg><\/span>Practical consideration for foreign sponsors<\/h3>\n<p>A Colombian Sponsor\u2013CRO Responsibility Matrix can help identify whether the allocation contained in a global CRO agreement actually covers the obligations that arise under Colombian regulation.<\/p>\n<\/div>\n\n<h2>What Should Be Included in the Initial INVIMA Clinical Trial Submission?<\/h2>\n<figure class=\"nc-figure\"><img data-src=\"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/5-1.jpg\" alt=\"What Should Be Included in the Initial INVIMA Clinical Trial Submission\" width=\"1376\" height=\"768\" decoding=\"async\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1376px; --smush-placeholder-aspect-ratio: 1376\/768;\"><\/figure>\n<p>The initial submission to INVIMA requires a structured regulatory dossier.<\/p>\n<p>According to the current INVIMA guidance identified in the regulatory review, the submission may include, among other documents:<\/p>\n<ul class=\"nc-checks\">\n<li>the clinical protocol in Spanish and English;<\/li>\n<li>the applicable INVIMA verification form;<\/li>\n<li>Ethics Committee documentation and approval;<\/li>\n<li>the Investigator&#8217;s Brochure;<\/li>\n<li>informed-consent documents;<\/li>\n<li>site and investigator documentation;<\/li>\n<li>the applicable insurance policy;<\/li>\n<li>Good Manufacturing Practice documentation for the manufacturer; and<\/li>\n<li>technical and quality documentation relating to the investigational product.<\/li>\n<\/ul>\n<p>The exact documentation should be confirmed for the specific study and product before filing.<\/p>\n<div class=\"nc-key\"><p><strong>Commercially important:<\/strong> A sponsor should not treat the Colombian submission as a simple local translation of the FDA or EMA dossier. Local ethics, insurance, site and product-documentation requirements need to be mapped separately.<\/p><\/div>\n\n<h2>What Regulatory Obligations Continue After INVIMA Approval?<\/h2>\n<figure class=\"nc-figure\"><img data-src=\"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/6-1.jpg\" alt=\"What Regulatory Obligations Continue After INVIMA Approval\" width=\"1376\" height=\"768\" decoding=\"async\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1376px; --smush-placeholder-aspect-ratio: 1376\/768;\"><\/figure>\n<p>INVIMA approval is not the end of the Colombian regulatory process.<\/p>\n<p>During the conduct of the study, the sponsor and, where applicable, the CRO must continue to manage regulatory obligations relating to amendments, new sites, new investigators, informed-consent changes, safety information and other changes affecting the approved study.<\/p>\n<p>The regulatory review also identifies obligations involving annual reports, pharmacovigilance, investigational-product traceability, monitoring, quality assurance and maintenance of essential documentation.<\/p>\n<p>Relevant amendments generally require approval before implementation, except where urgent measures are necessary to eliminate an immediate risk to participants.<\/p>\n<p>At the end of the study, the sponsor must also address the regulatory closure process, including final documentation and investigational-product accountability.<\/p>\n<div class=\"nc-box\">\n<h3><span class=\"nc-box-icon\" aria-hidden=\"true\"><svg width=\"20\" height=\"20\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"#a8823f\" stroke-width=\"2.2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><circle cx=\"12\" cy=\"12\" r=\"10\"\/><polyline points=\"12 6 12 12 16 14\"\/><\/svg><\/span>Safety reporting requires particular attention<\/h3>\n<p>For serious adverse events occurring in Colombia, the source material identifies reporting obligations involving the investigator, sponsor, Ethics Committee and INVIMA, including a <strong>24-hour reporting period<\/strong> to the sponsor and Ethics Committee and a <strong>seven-business-day period<\/strong> for the sponsor or CRO to report to INVIMA, together with the applicable follow-up.<\/p>\n<\/div>\n<div class=\"nc-note\"><p><strong>For global sponsors:<\/strong> Colombian safety-reporting obligations should be incorporated into the global pharmacovigilance SOPs and escalation calendar.<\/p><\/div>\n\n<h2>How Should Investigational Products and Biological Samples Be Managed Across Borders?<\/h2>\n<figure class=\"nc-figure\"><img data-src=\"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/7-1.jpg\" alt=\"How Should Investigational Products and Biological Samples Be Managed Across Borders\" width=\"1376\" height=\"768\" decoding=\"async\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1376px; --smush-placeholder-aspect-ratio: 1376\/768;\"><\/figure>\n<p>Investigational-product logistics and biological-sample transfers should be addressed early in the Colombian regulatory strategy.<\/p>\n<p>INVIMA has a specific procedure for applications related to the importation of clinical-trial supplies and the exportation of biological samples associated with clinical-research protocols.<\/p>\n<p>The investigational product must remain identifiable and traceable throughout the study, including records concerning shipment, receipt, return and destruction.<\/p>\n<p>Where biological samples will be exported, the relevant documentation should address matters such as the type of sample, purpose of the analysis, storage conditions, destination and the party responsible for the process.<\/p>\n<p>The regulatory strategy should also be aligned with the protocol and informed-consent documentation.<\/p>\n<p class=\"nc-streams-title\">In practice, sponsors should address two separate workstreams<\/p>\n<div class=\"nc-streams\">\n<div class=\"nc-stream is-a\">\n<h3><svg width=\"20\" height=\"20\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"#dcc08f\" stroke-width=\"2.2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" aria-hidden=\"true\"><path d=\"M21 16V8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16z\"\/><polyline points=\"3.27 6.96 12 12.01 20.73 6.96\"\/><line x1=\"12\" y1=\"22.08\" x2=\"12\" y2=\"12\"\/><\/svg>Investigational product<\/h3>\n<ul><li>Importation<\/li><li>Storage<\/li><li>Receipt<\/li><li>Accountability<\/li><li>Return or destruction<\/li><\/ul>\n<\/div>\n<div class=\"nc-stream is-b\">\n<h3><svg width=\"20\" height=\"20\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"#ffffff\" stroke-width=\"2.2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" aria-hidden=\"true\"><path d=\"M9 2v6L4 18a2 2 0 0 0 1.8 3h12.4A2 2 0 0 0 20 18L15 8V2\"\/><path d=\"M8 2h8\"\/><path d=\"M7 14h10\"\/><\/svg>Biological samples<\/h3>\n<ul><li>Type of sample<\/li><li>Purpose of analysis<\/li><li>Destination<\/li><li>Storage conditions<\/li><li>Responsible party<\/li><li>Confidentiality<\/li><li>Informed-consent coverage<\/li><\/ul>\n<\/div>\n<\/div>\n\n<h2>What Should Foreign Sponsors Know About Clinical Data, Medical Records and Cross-Border Transfers?<\/h2>\n<figure class=\"nc-figure\"><img data-src=\"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/8-1.jpg\" alt=\"What Should Foreign Sponsors Know About Clinical Data, Medical Records and Cross-Border Transfers\" width=\"1376\" height=\"768\" decoding=\"async\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1376px; --smush-placeholder-aspect-ratio: 1376\/768;\"><\/figure>\n<p>Clinical trials involve health information and other categories of sensitive personal data that are subject to Colombian data-protection requirements.<\/p>\n<p>Foreign sponsors should identify the roles of the sponsor, CRO, research site and other providers in the processing of personal data and determine whether the relevant data flows constitute international transfers or international transmissions.<\/p>\n<div class=\"nc-note\"><p><strong>This distinction can be legally relevant under the Colombian data-protection framework.<\/strong><\/p><\/div>\n<p>Medical records are also subject to confidentiality rules, while biological samples, genetic studies, pharmacogenomic analyses and future uses of samples should be appropriately reflected in the protocol, informed consent and regulatory documentation.<\/p>\n<p>Where samples are transferred outside Colombia, the regulatory requirements applicable to their export must also be considered.<\/p>\n<div class=\"nc-key\"><p><strong>For international sponsors:<\/strong> Compliance with GDPR, HIPAA or a global privacy policy does not by itself resolve the Colombian legal analysis of clinical-data flows.<\/p><\/div>\n\n<h2>Why Do Advanced Therapies Require an Early Colombian Regulatory Assessment?<\/h2>\n<figure class=\"nc-figure\"><img data-src=\"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/9-1.jpg\" alt=\"Why Do Advanced Therapies Require an Early Colombian Regulatory Assessment\" width=\"1376\" height=\"768\" decoding=\"async\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1376px; --smush-placeholder-aspect-ratio: 1376\/768;\"><\/figure>\n<p>Cell therapies, gene therapies, CAR-T products and other highly personalized treatments may require a more complex Colombian regulatory analysis.<\/p>\n<p>The source material notes that advanced therapies may raise additional issues relating to product classification, manufacturing, quality, importation, biological samples, genetic information and long-term safety.<\/p>\n<p>For these products, a sponsor should not assume that the regulatory classification or pathway adopted by FDA or EMA will automatically determine the Colombian approach.<\/p>\n<p>An early regulatory assessment may therefore be particularly valuable before the sponsor finalizes the Colombian operational structure, selects sites or commits to an importation and sample-handling strategy.<\/p>\n<div class=\"nc-key\"><p>Advanced-therapy sponsors should address classification and regulatory pathway questions before site activation, rather than after the Colombian study structure has already been established.<\/p><\/div>\n\n<p class=\"nc-eyebrow\">What Should Be Included in the Initial INVIMA Clinical Trial Submission?<\/p>\n<h2>Do Not Treat the Colombian Submission as a Translation Exercise<\/h2>\n<figure class=\"nc-figure\"><img data-src=\"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/10-1.jpg\" alt=\"Do Not Treat the Colombian Submission as a Translation Exercise\" width=\"1376\" height=\"768\" decoding=\"async\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1376px; --smush-placeholder-aspect-ratio: 1376\/768;\"><\/figure>\n<p>A Colombian clinical-trial submission should not be approached as a simple translation or administrative adaptation of an FDA, EMA or other foreign regulatory dossier.<\/p>\n<p>Local requirements must be mapped independently, particularly in relation to Ethics Committee documentation, informed consent, insurance, site and investigator documentation, manufacturing evidence, and technical and quality information relating to the investigational product.<\/p>\n<div class=\"nc-note\"><p><strong>For foreign sponsors:<\/strong> the Colombian submission strategy should be reviewed before filing to identify local gaps that may not be addressed in the global regulatory package.<\/p><\/div>\n\n<section class=\"nc-ready\">\n<div class=\"nc-ready-head\"><h2>Planning a Clinical Trial in Colombia? Request a Regulatory Readiness Assessment<\/h2><\/div>\n<div class=\"nc-ready-img\"><img data-src=\"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/11-1.jpg\" alt=\"Planning a Clinical Trial in Colombia? Request a Regulatory Readiness Assessment\" width=\"1376\" height=\"768\" decoding=\"async\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1376px; --smush-placeholder-aspect-ratio: 1376\/768;\"><\/div>\n<div class=\"nc-ready-body\">\n<p>Nieto &amp; Nieto Lawyers advises foreign pharmaceutical companies, biotech companies, sponsors and CROs on the Colombian legal and regulatory workstream of clinical trials.<\/p>\n<p>A Colombia Clinical Trial Regulatory Readiness Assessment can be used to identify legal and regulatory issues before submission or site activation, including:<\/p>\n<ul class=\"nc-checks\">\n<li>INVIMA regulatory pathway;<\/li>\n<li>site qualification;<\/li>\n<li>sponsor\u2013CRO responsibility allocation;<\/li>\n<li>Ethics Committee requirements;<\/li>\n<li>investigational-product logistics;<\/li>\n<li>biological-sample exports;<\/li>\n<li>clinical-data flows;<\/li>\n<li>insurance and indemnity issues;<\/li>\n<li>Clinical Trial Agreements; and<\/li>\n<li>ongoing Colombian regulatory obligations.<\/li>\n<\/ul>\n<\/div>\n<\/section>\n\n<section class=\"nc-final\">\n<p class=\"nc-eyebrow\">What Regulatory Obligations Continue After INVIMA Approval?<\/p>\n<h2>INVIMA Approval Is Not the End of the Regulatory Process<\/h2>\n<figure class=\"nc-figure\"><img data-src=\"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/12-1.jpg\" alt=\"INVIMA Approval Is Not the End of the Regulatory Process\" width=\"1376\" height=\"768\" decoding=\"async\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1376px; --smush-placeholder-aspect-ratio: 1376\/768;\"><\/figure>\n<p>Authorization of the initial protocol is only one stage of the Colombian regulatory lifecycle.<\/p>\n<p>During the study, sponsors and CROs may need to manage ongoing obligations relating to amendments, new sites and investigators, informed-consent changes, safety information, annual reporting, pharmacovigilance, investigational-product traceability, monitoring and maintenance of essential documentation.<\/p>\n<p>At study completion, the regulatory workstream continues through closure, final documentation and investigational-product accountability.<\/p>\n<ol class=\"nc-timeline\" aria-label=\"INVIMA Approval \u2192 Amendments \u2192 Safety Reporting \u2192 Annual Reporting \u2192 Product Accountability \u2192 Study Closure\">\n<li>INVIMA Approval<\/li>\n<li>Amendments<\/li>\n<li>Safety Reporting<\/li>\n<li>Annual Reporting<\/li>\n<li>Product Accountability<\/li>\n<li>Study Closure<\/li>\n<\/ol>\n<div class=\"nc-btn-wrap\"><a class=\"nc-btn is-navy\" href=\"https:\/\/wa.me\/573156695219?text=Hello%2C%20I%20read%20your%20article%20on%20clinical%20trials%20in%20Colombia%20and%20I%20would%20like%20to%20request%20a%20Colombia%20clinical%20trial%20assessment.\" target=\"_blank\" rel=\"noopener\">REQUEST A COLOMBIA CLINICAL TRIAL ASSESSMENT \u2192<\/a><\/div>\n<div class=\"nc-note\"><p><strong>For global sponsors:<\/strong> these Colombian obligations should be incorporated into the study&#8217;s regulatory calendar and operational responsibilities from the outset.<\/p><\/div>\n<\/section>\n\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conducting a clinical trial in Colombia involves more than obtaining INVIMA approval. Foreign pharmaceutical companies, biotech companies and CROs must coordinate regulatory approval, ethics review, site qualification, healthcare-service habilitation, investigational-product logistics, safety reporting, data protection and contractual allocation of responsibilities. A deficiency in any of these areas may affect submission, site activation or the ongoing [&hellip;]<\/p>\n","protected":false},"featured_media":2893,"template":"","meta":[],"categoria":[36],"class_list":["post-2892","actualidad","type-actualidad","status-publish","has-post-thumbnail","hentry","categoria-regulatory-compliance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Clinical Trials in Colombia: INVIMA Requirements for Foreign Sponsors &amp; CROs - Nieto &amp; Nieto Lawyers<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nietolawyers.com\/en\/actualidad\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical Trials in Colombia: INVIMA Requirements for Foreign Sponsors &amp; CROs - Nieto &amp; Nieto Lawyers\" \/>\n<meta property=\"og:description\" content=\"Conducting a clinical trial in Colombia involves more than obtaining INVIMA approval. Foreign pharmaceutical companies, biotech companies and CROs must coordinate regulatory approval, ethics review, site qualification, healthcare-service habilitation, investigational-product logistics, safety reporting, data protection and contractual allocation of responsibilities. A deficiency in any of these areas may affect submission, site activation or the ongoing [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nietolawyers.com\/en\/actualidad\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\/\" \/>\n<meta property=\"og:site_name\" content=\"Nieto &amp; Nieto Lawyers\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/NietoLawyers\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-14T15:40:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/1-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1376\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/actualidad\\\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\\\/\",\"url\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/actualidad\\\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\\\/\",\"name\":\"Clinical Trials in Colombia: INVIMA Requirements for Foreign Sponsors &amp; CROs - Nieto &amp; Nieto Lawyers\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/actualidad\\\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/actualidad\\\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/1-3.jpg\",\"datePublished\":\"2026-10-14T15:40:33+00:00\",\"dateModified\":\"2026-10-14T15:40:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/actualidad\\\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nietolawyers.com\\\/en\\\/actualidad\\\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/actualidad\\\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/1-3.jpg\",\"contentUrl\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/1-3.jpg\",\"width\":1376,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/actualidad\\\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualidad\",\"item\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/actualidad\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Clinical Trials in Colombia: INVIMA Requirements for Foreign Sponsors &amp; CROs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/\",\"name\":\"Nieto & Nieto Lawyers En\",\"description\":\"Nieto &amp; Nieto Lawyers\",\"publisher\":{\"@id\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/#organization\",\"name\":\"Nieto & Nieto Lawyers\",\"url\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/TESTNN.png\",\"contentUrl\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/TESTNN.png\",\"width\":461,\"height\":119,\"caption\":\"Nieto & Nieto Lawyers\"},\"image\":{\"@id\":\"https:\\\/\\\/nietolawyers.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/NietoLawyers\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical Trials in Colombia: INVIMA Requirements for Foreign Sponsors &amp; CROs - Nieto &amp; Nieto Lawyers","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nietolawyers.com\/en\/actualidad\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\/","og_locale":"en_US","og_type":"article","og_title":"Clinical Trials in Colombia: INVIMA Requirements for Foreign Sponsors &amp; CROs - Nieto &amp; Nieto Lawyers","og_description":"Conducting a clinical trial in Colombia involves more than obtaining INVIMA approval. Foreign pharmaceutical companies, biotech companies and CROs must coordinate regulatory approval, ethics review, site qualification, healthcare-service habilitation, investigational-product logistics, safety reporting, data protection and contractual allocation of responsibilities. A deficiency in any of these areas may affect submission, site activation or the ongoing [&hellip;]","og_url":"https:\/\/nietolawyers.com\/en\/actualidad\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\/","og_site_name":"Nieto &amp; Nieto Lawyers","article_publisher":"https:\/\/www.facebook.com\/NietoLawyers\/","article_modified_time":"2026-10-14T15:40:34+00:00","og_image":[{"width":1376,"height":768,"url":"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/1-3.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nietolawyers.com\/en\/actualidad\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\/","url":"https:\/\/nietolawyers.com\/en\/actualidad\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\/","name":"Clinical Trials in Colombia: INVIMA Requirements for Foreign Sponsors &amp; CROs - Nieto &amp; Nieto Lawyers","isPartOf":{"@id":"https:\/\/nietolawyers.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nietolawyers.com\/en\/actualidad\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\/#primaryimage"},"image":{"@id":"https:\/\/nietolawyers.com\/en\/actualidad\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\/#primaryimage"},"thumbnailUrl":"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/1-3.jpg","datePublished":"2026-10-14T15:40:33+00:00","dateModified":"2026-10-14T15:40:34+00:00","breadcrumb":{"@id":"https:\/\/nietolawyers.com\/en\/actualidad\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nietolawyers.com\/en\/actualidad\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nietolawyers.com\/en\/actualidad\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\/#primaryimage","url":"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/1-3.jpg","contentUrl":"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2026\/10\/1-3.jpg","width":1376,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/nietolawyers.com\/en\/actualidad\/clinical-trials-in-colombia-invima-requirements-for-foreign-sponsors-cros\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nietolawyers.com\/en\/"},{"@type":"ListItem","position":2,"name":"Actualidad","item":"https:\/\/nietolawyers.com\/en\/actualidad\/"},{"@type":"ListItem","position":3,"name":"Clinical Trials in Colombia: INVIMA Requirements for Foreign Sponsors &amp; CROs"}]},{"@type":"WebSite","@id":"https:\/\/nietolawyers.com\/en\/#website","url":"https:\/\/nietolawyers.com\/en\/","name":"Nieto & Nieto Lawyers En","description":"Nieto &amp; Nieto Lawyers","publisher":{"@id":"https:\/\/nietolawyers.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nietolawyers.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/nietolawyers.com\/en\/#organization","name":"Nieto & Nieto Lawyers","url":"https:\/\/nietolawyers.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nietolawyers.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2023\/07\/TESTNN.png","contentUrl":"https:\/\/nietolawyers.com\/en\/wp-content\/uploads\/2023\/07\/TESTNN.png","width":461,"height":119,"caption":"Nieto & Nieto Lawyers"},"image":{"@id":"https:\/\/nietolawyers.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/NietoLawyers\/"]}]}},"_links":{"self":[{"href":"https:\/\/nietolawyers.com\/en\/wp-json\/wp\/v2\/actualidad\/2892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nietolawyers.com\/en\/wp-json\/wp\/v2\/actualidad"}],"about":[{"href":"https:\/\/nietolawyers.com\/en\/wp-json\/wp\/v2\/types\/actualidad"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nietolawyers.com\/en\/wp-json\/wp\/v2\/media\/2893"}],"wp:attachment":[{"href":"https:\/\/nietolawyers.com\/en\/wp-json\/wp\/v2\/media?parent=2892"}],"wp:term":[{"taxonomy":"categoria","embeddable":true,"href":"https:\/\/nietolawyers.com\/en\/wp-json\/wp\/v2\/categoria?post=2892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}